At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
bevacizumab +2 moredrug
Likely dose
bevacizumab 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Capecitabine, Carboplatin, and Bevacizumab for Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating bevacizumab, carboplatin, and 1 other intervention for Stomach Cancer and 3 related conditions. Completed, enrolled 35 participants across 1 site.
Detailed Summary
To investigate bevacizumab in combination with carboplatin and capecitabine for patients with unresectable or metastatic GEJ or gastric cancers. We hope that by adding bevacizumab to standard chemotherapy for this patient population we will improve Progression Free Survival by 90% over historical controls.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStomach Cancer, Gastric (Stomach) Cancer, Neoplasm of Cardioesophageal Junction, Gastrointestinal Stromal Tumor (GIST)
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartFeb 2009
Primary CompletionDec 2017
TodayJul 2026
First PostedOct 27, 2008
Enrollment StartFeb 1, 2009
Primary CompletionDec 31, 2017
TodayJul 2, 2026
Enrollment to primary: 8.9 yearsPosted 17.7 years ago
Interventions
bevacizumabdrug
Intravenous 15 mg/kg
carboplatindrug
AUC 6, Intravenously Day 1 every 21 days
capecitabinedrug
850mg/m2, Orally twice daily days 1-14 every 21 days.